C11482: PSMA-based Theranostic Imaging of Metastatic CancerNovelty:
This invention is a pharmaceutical composition and method for the effective imaging, targeting, and treatment of metastatic tumor cells.
Value Proposition:
In the United States, prostate cancer (PCa) is the second leading cause of cancer-related death among men. There is a compelling need to find effective treatments for metastatic cancers, including PCa. The technology described here enables the systemic delivery of drugs to diseased cells while leaving healthy cells intact and confirms its therapeutic efficacy using non-invasive methods. Besides applications in oncology, the technology can be altered to extend its scope and functionality to treat other ailments, including neurologic disorders, cardiovascular disease, and viral infections. Advantages include:
• Selectively kills tumor cells, while maintaining the health of neighboring tissues.
• Uses existing clinical imaging machinery to rapidly detect therapeutic distribution of drug, optimize drug safety, and observe therapeutic effects.
• Assists in streamlining the drug development process.
.
• Easily modified and applicable to treat different cancers, receptors, and pathways.
• Improves treatment regimens by tailoring the system to fit an individual’s tumor profile.
Technical Details:
Johns Hopkins researchers have developed a prostate specific membrane antigen (PSMA) based nanoplex platform that allows for the selective targeting, drug delivery, and diagnostic imaging of prostate cancer cells. This theranostic approach integrates molecular diagnostic tests and targeted therapeutics in an interdependent, collaborative manner. Specifically, prostate specific membrane antigen (PSMA) targeted structures carrying multimodality imaging reporters, small interfering RNA (siRNA), and enzymes are packaged together for a theranostic approach to human cancer. The goal is to individualize treatment by targeting therapy to a specific disease subtype and genetic profile. The strategies developed here can be extended to down-regulate multi-drug resistance pathways, or repair enzymes to increase the efficiency of chemo- or radiation therapy. This is a “platform” technology and the nanoplex can be targeted to cell surface markers other than PSMA, like CXCR4. It is useful for disorders other than cancer (e.g. neurological, cardiovascular, and viral).
Looking for Partners:
To develop and commercialize the technology as a combined imaging and anti-cancer therapeutic agent for prostate cancer.
Stage of Development:
Pre-Clinical
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
Not available at this time
Patent Information:
| Title |
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
Patent Status |
| PSMA-based Theranostic Imaging of Metastatic Cancer |
PCT: Patent Cooperation Treaty |
United States |
14/008,715 |
10,029,023 |
2/27/2014 |
7/24/2018 |
12/28/2033 |
Granted |
